GALT
Galectin Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$144.16M
P/E Ratio
—
EPS
$-0.48
Beta
1.04
52W High
$7.13
52W Low
$1.21
50-Day MA
$2.94
200-Day MA
$3.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
4.54
PEG Ratio
0.00
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -3728.00% |
| Return on Assets | -67.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-1.97 |
| Price-to-Book | 207.70 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.04 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $65.83M |
| Float | $47.16M |
| % Insiders | 29.10% |
| % Institutions | 17.64% |
Data last updated: 4/8/2026